全文获取类型
收费全文 | 10109篇 |
免费 | 804篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 145篇 |
儿科学 | 196篇 |
妇产科学 | 151篇 |
基础医学 | 1173篇 |
口腔科学 | 104篇 |
临床医学 | 1059篇 |
内科学 | 2144篇 |
皮肤病学 | 128篇 |
神经病学 | 836篇 |
特种医学 | 377篇 |
外科学 | 2070篇 |
综合类 | 125篇 |
一般理论 | 11篇 |
预防医学 | 811篇 |
眼科学 | 228篇 |
药学 | 616篇 |
中国医学 | 12篇 |
肿瘤学 | 767篇 |
出版年
2024年 | 15篇 |
2023年 | 151篇 |
2022年 | 225篇 |
2021年 | 585篇 |
2020年 | 299篇 |
2019年 | 486篇 |
2018年 | 543篇 |
2017年 | 361篇 |
2016年 | 366篇 |
2015年 | 395篇 |
2014年 | 554篇 |
2013年 | 652篇 |
2012年 | 976篇 |
2011年 | 903篇 |
2010年 | 502篇 |
2009年 | 401篇 |
2008年 | 595篇 |
2007年 | 581篇 |
2006年 | 510篇 |
2005年 | 468篇 |
2004年 | 405篇 |
2003年 | 345篇 |
2002年 | 247篇 |
2001年 | 34篇 |
2000年 | 16篇 |
1999年 | 31篇 |
1998年 | 37篇 |
1997年 | 30篇 |
1996年 | 28篇 |
1995年 | 21篇 |
1994年 | 18篇 |
1993年 | 19篇 |
1992年 | 12篇 |
1991年 | 12篇 |
1990年 | 12篇 |
1989年 | 6篇 |
1988年 | 7篇 |
1987年 | 6篇 |
1986年 | 7篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1983年 | 11篇 |
1982年 | 6篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1976年 | 9篇 |
1972年 | 3篇 |
1963年 | 3篇 |
1955年 | 3篇 |
1954年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. 总被引:6,自引:0,他引:6
Charles T Miller Justin R Moy Lin Lin Matthew Schipper Daniel Normolle Dean E Brenner Mark D Iannettoni Mark B Orringer David G Beer 《Clinical cancer research》2003,9(13):4819-4825
PURPOSE: The purpose of this study was to determine the frequency and overall contribution of specific gene amplification events in the formation of Barrett's adenocarcinomas. The relationship of gene amplification to clinical-pathological variables and its potential usefulness as a marker for early cancer detection were also examined. EXPERIMENTAL DESIGN: We used quantitative PCR and Southern blot analysis to screen 87 cases of Barrett's adenocarcinoma for the presence or absence of 13 distinct gene amplification events. Gene amplification was then examined for correlation with other amplification events and clinical variables (survival, stage, nodal involvement, tumor invasion, smoking history, and gender). Additionally, 22 specimens of Barrett's with high-grade dysplasia (HGD) were examined for the presence of gene amplification. RESULTS: One or more amplification events were present in 50 of 87 (57%) adenocarcinomas. The ERBB2 gene was amplified in 19 of 87 (21.8%), CCNE1 in 11 of 87 (12.6%), GATA4 in 9 of 87 (10.3%), KRAS in 9 of 87 (10.3%), EGFR in 7 of 87 (8.0%), CCND1 in 6 of 87 (6.8%), HNF3alpha in 5 of 87 (5.7%), PIK3CA in 5 of 87 (5.7%), C-MYC in 4 of 87 (4.6%), DYRK2 in 2 of 87 (2.3%), and AIB1, AKT1, and IGF1R were amplified in 0 of 87 (0%) of the tumors. CCND1 amplification was found to correlate negatively with survival (P < 0.05). In addition, the ERBB2 amplicon positively correlated (P < 0.05) with GATA4 amplification. Increased copy number of the ERBB2 (1 of 22), GATA4 (1 of 22), KRAS (2 of 22), C-MYC (1 of 22), CCNE1 (2 of 22), and CCND1 (2 of 22) genes was also observed in one or more Barrett's adenocarcinomas with HGD. CONCLUSIONS: The high frequency of gene amplification in esophageal adenocarcinomas and HGD indicates the important role of these events in esophageal adenocarcinoma development. Additionally, these results underscore the possible usefulness of early detection approaches and chemotherapeutic strategies (ErbB2 and cyclin D1) targeted against amplified gene products. 相似文献
62.
Marisa L Kreider Justin E Aldridge Mandy M Cousins Colleen A Oliver Frederic J Seidler Theodore A Slotkin 《Neuropsychopharmacology》2005,30(10):1841-1855
Glucocorticoids are the consensus treatment for the prevention of respiratory distress in preterm infants, but there is evidence for increased incidence of neurodevelopmental disorders as a result of their administration. We administered dexamethasone (Dex) to developing rats at doses below or within the range of those used clinically, evaluating the effects on forebrain development with exposure in three different stages: gestational days 17-19, postnatal days 1-3, or postnatal days 7-9. At 24 h after the last dose, we evaluated biomarkers of neural cell acquisition and growth, synaptic development, neurotransmitter receptor expression, and synaptic signaling mediated by adenylyl cyclase (AC). Dex impaired the acquisition of neural cells, with a peak effect when given in the immediate postnatal period. In association with this defect, Dex also elicited biphasic effects on cholinergic presynaptic development, promoting synaptic maturation at a dose (0.05 mg/kg) well below those used therapeutically, whereas the effect was diminished or lost when doses were increased to 0.2 or 0.8 mg/kg. Dex given postnatally also disrupted the expression of adrenergic receptors known to participate in neurotrophic modeling of the developing brain and evoked massive induction of AC activity. As a consequence, disparate receptor inputs all produced cyclic AMP overproduction, a likely contributor to disrupted patterns of cell replication, differentiation, and apoptosis. Superimposed on the heterologous AC induction, Dex impaired specific receptor-mediated cholinergic and adrenergic signals. These results indicate that, during a critical developmental period, Dex administration leads to widespread interference with forebrain development, likely contributing to eventual, adverse neurobehavioral outcomes. 相似文献
63.
Janet Li Paul Roche Jenean Spencer Ivan Bastian Amanda Christensen Mark Hurwitz Anastasios Konstantinos Vicki Krause Moira McKinnon Avner Misrachi Graham Tallis Justin Waring 《Communicable diseases intelligence》2004,28(4):464-473
The National Notifiable Disease Surveillance System (NNDSS) received 982 tuberculosis (TB) notifications in 2003, of which 947 were new cases, 33 were relapses and two were cases with unknown history. The incidence of TB in Australia has remained at a stable rate since 1985 and was 4.9 cases per 100,000 population in 2003. The high-incidence groups remain people born overseas and Indigenous Australians at 19.9 and 8.7 cases per 100,000 population, respectively. By contrast the incidence in non-Indigenous Australians was 0.9 per 100,000. Comparison of the 2003 TB notification data against the performance indicators set by National Tuberculosis Advisory Committee highlights that enhanced TB control measures should be considered among these high-risk groups. 相似文献
64.
Louis B Cooper Dylan K Chan Frederick C Roediger Brian R Shaffer Justin F Fraser Sergei Musatov Samuel H Selesnick Michael G Kaplitt 《Otology & neurotology》2006,27(4):484-490
HYPOTHESIS: Delivery of the gene encoding X-linked inhibitor of apoptosis (XIAP) using an adeno-associated viral (AAV) vector can protect against cisplatin-mediated ototoxicity. BACKGROUND: Cisplatin is a widely used chemotherapeutic agent with significant ototoxic side effects. One possible mechanism of toxicity is apoptotic death of many cochlear cell types. Acute treatment with inhibitors of caspases- enzymes critical for apoptosis- has been shown to prevent hearing loss in vivo, but is too short-acting for therapeutic use. Gene therapy provides a specific and chronic means of delivering potential therapeutic gents. Introducing an anti-apoptotic gene into the cochlea could provide long-term prophylaxis against the ototoxic effects of cisplatin. METHOD: Two groups of rats were treated with unilateral injection into the round window of AAV harboring a gene encoding either XIAP or green fluorescent protein (GFP). After at least two months of gene expression, auditory-brainstem-response (ABR) threshold shifts and outer-hair-cell (OHC) number were measured in these two groups of animals after 72-hour treatment with cisplatin. RESULTS: Consistent with previous reports, uninjected and AAV.GFP-injected ears displayed profound ABR threshold elevations and OHC loss after cisplatin treatment. Ears that had been injected with AAV encoding XIAP, however, were significantly protected from these effects: cisplatin-induced ABR-threshold shift and hair-cell loss were attenuated by as much as 78% and 45%, respectively, when compared with contralateral (untreated) ears. CONCLUSION: XIAP delivery to the cochlea can protect against the audiometric changes and hair-cell loss associated with cisplatin ototoxicity. The efficacy, specificity, and duration of the protective effects make this a potentially attractive therapeutic paradigm. 相似文献
65.
Dan W Haupt Angela Luber Justin Maeda Angela K Melson Julie A Schweiger John W Newcomer 《Neuropsychopharmacology》2005,30(1):184-191
Alterations in plasma leptin have been reported in schizophrenia patients treated with antipsychotics, suggesting the hypothesis that impairments in leptin secretion or signaling might play a role in antipsychotic-induced weight gain. Plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n=27), risperidone (n=24) or typical antipsychotics (n=21) and 124 healthy adult control subjects. ANCOVA was used to test effects of adiposity (body mass index kg/m2; BMI), subject group (treated patients vs untreated controls), and treatment group (specific medication groups and untreated controls) on plasma leptin concentrations. Additional analyses were performed in a subset of patients and controls individually matched for BMI to further assess group differences in plasma leptin independent of adiposity. BMI strongly predicted plasma leptin concentrations in the overall sample. In addition, a significant three-way interaction between BMI, subject group, and gender was observed. In the individually BMI-matched sample, modestly reduced plasma leptin levels (effect size 0.4 SD) were observed in treated patients in comparison to the BMI-matched healthy controls, with both groups including males and females. However, no differences in plasma leptin levels were observed in the matched sample when separately comparing male patients vs untreated male controls and female patients vs untreated female controls. Plasma leptin in chronically treated patients with schizophrenia is strongly predicted by adiposity, similar to untreated healthy individuals despite adequate power to detect a difference. The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications. 相似文献
66.
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. 总被引:7,自引:0,他引:7
E Ramsay Camp Justin Summy Todd W Bauer Wenbiao Liu Gary E Gallick Lee M Ellis 《Clinical cancer research》2005,11(1):397-405
Targeted therapies that inhibit the activity of tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR) have shown activity against solid malignancies when used as single agents or in combination with chemotherapy. Although anti-EGFR therapies are active in some patients, eventually disease in nearly all patients will become refractory to therapy. Therefore, a better understanding of the mechanisms of resistance to anti-EGFR therapies is critical to further improve the efficacy of this class of agents. Mechanisms that mediate resistance to anti-EGFR therapies include the presence of redundant tyrosine kinase receptors, increased angiogenesis, and the constitutive activation of downstream mediators. Two recent landmark publications have also shown that specific mutations in the kinase domain of EGFR in some lung carcinomas are associated with markedly improved response rates to an EGFR tyrosine kinase inhibitor. Mutations in the EGFR receptor seem to play a significant role in determining the sensitivity of tumor cells to EGFR inhibitor therapy by altering the conformation and activity of the receptor. As the field of molecular therapeutics continues to evolve, a comprehensive understanding of resistance mechanisms will ultimately lead to refinements in our regimens to provide better care for patients with cancer. 相似文献
67.
68.
69.
François-Clément Bidard Dieter J Peeters Tanja Fehm Franco Nolé Rafael Gisbert-Criado Dimitrios Mavroudis Salvatore Grisanti Daniele Generali Jose A Garcia-Saenz Justin Stebbing Carlos Caldas Paola Gazzaniga Luis Manso Rita Zamarchi Angela Fernandez de Lascoiti Leticia De Mattos-Arruda Michail Ignatiadis Ronald Lebofsky Stefan Michiels 《The lancet oncology》2014,15(4):406-414
70.
Jean-Baptiste Bouillon-Minois Justin Outrey Bruno Pereira Oluwaseun John Adeyemi Vincent Sapin Damien Bouvier David Thivel Sarah de Saint-Vincent Ukadike Chris Ugbolue Julien S. Baker Reza Bagheri Jeannot Schmidt Marion Trousselard Frdric Dutheil 《Nutrients》2022,14(23)
Despite the available literature on the consequences of night shiftwork on stress and food intake, its impact on leptin and ghrelin has never been studied. We previously demonstrated that leptin and ghrelin were biomarkers related to stress, and acute stress-induced a decrease in leptin levels and an increase in ghrelin levels. We performed a prospective observational study to assess the influence of night work, nutrition, and stress on the levels of ghrelin and leptin among emergency healthcare workers (HCWs). We took salivary samples at the beginning of a day shift and/or at the end of a night shift. We also monitored stress using the job demand-control-support model of Karasek. We recorded 24-h food intake during the day shift and the consecutive night shift and during night work and the day before. We included 161 emergency HCWs. Emergency HCWs had a tendency for decreased levels of leptin following the night shift compared to before the dayshift (p = 0.067). Furthermore, the main factors explaining the decrease in leptin levels were an increase in job-demand (coefficient −54.1, 95 CI −99.0 to −0.92) and a decrease in job control (−24.9, −49.5 to −0.29). Despite no significant changes in ghrelin levels between shifts, social support was the main factor explaining the increase in ghrelin (6.12, 0.74 to 11.5). Food intake (kcal) also had a negative impact on leptin levels, in addition to age. Ghrelin levels also decreased with body mass index, while age had the opposite effect. In conclusion, we confirmed that ghrelin and leptin as biomarkers of stress were directly linked to the job demand-control-support model of Karasek, when the main cofounders were considered. 相似文献